Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...